|Cell Type||Cor.4U human iPSC-derived cardiomyocytes or co-cultures with FibroCor.4U human iPSC-derived cardiac fibroblasts|
|Cell Source||Human iPSC of 26 y/o Caucasian female|
|Service type||Biomechanical analysis|
|Delivery||A study protocol will be sent to initiate the study|
|Timeline||Draft report will be sent within 7 weeks after receipt of test compounds|
- True force measurement in human iPSC derived cardiomyocytes using proprietary Cor.4CE® assay technology
- Highly precise, standardized and repeatable test system
- Sensitive and predictive for cardiac safety pharmacology
- Suitable for scale-up given low compound volumes, quick turnaround
Read more about this new service also in BioInformants article
The CardioForce cardiac cell contractile force assay is based on the proprietary Cor.4CE® system developed by Axiogenesis, a non-invasive in vitro assay to measure true contractility of cardiomyocyte monolayers or co-cultures of cardiomyocytes with cardiac fibroblasts. Cor.4U® human iPSC-derived cardiomyocytes reveal mechanical properties typical for human cardiac myocytes (Goßmann et al, 2016). The Cor.4CE® system allows for repeatable contractility measurements with unprecedented accuracy under physiological mechanical boundary conditions. In contrast to surrogate technologies like impedance sensing, the Cor.4CE® system shows the expected physiological force-frequency-relationships for adrenergic stimulation.
The combination of Cor.4U with the Cor.4CE® system is the first in vitro assay setup to measure true contractile force of iPSC-derived cardiomyocytes in a system compatible with medium throughput. The system provides an ideal tool to assess pharmacological, safety pharmacological and toxicological effects of drug candidates on human cardiomyocytes.